comparemela.com

Latest Breaking News On - Biomarker selected patients - Page 1 : comparemela.com

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results News provided by Share this article Share this article CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/  Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020. 2020 Leap Highlights: Signed agreement with BeiGene, Ltd. for rights to Leap s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock Presented updated data from study of DKN-01 plus pembrolizumab in esophagogastric (EGC) cancer demonstrating positive outcomes in DKK1-high patients

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.